Biomedical Engineering
-
Arthritis drug could be first to stop heart valve calcification
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJun. 13, 2017
-
BME alumna honored with state STEM advocate award
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreMay. 29, 2017
-
Heart valve disease research earns grad student a young investigator award
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreApr. 24, 2017
-
Vanderbilt biomedical engineer receives presidential award for advanced wound healing research
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJan. 31, 2017
-
Researchers’ sensor integrates inflammatory bowel disease detection into colonoscopy procedure
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJan. 5, 2017
-
Biomedical engineering department pioneer, emeritus professor Ensign Johnson dies
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreNov. 7, 2016
-
Duvall earns spot on CMBE journal’s 2016 Young Innovators list
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreAug. 18, 2016
-
Churchwell named to new Chief Diversity Officer role at VUMC
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreJul. 15, 2016
-
Heart disease researcher to deliver Emerging Scholars Lecture April 19
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreApr. 11, 2016
-
Churchwell named to AIMBE College of Fellows
The first drug to treat calcification of heart valves may be one originally designed for rheumatoid arthritis. Today in Circulation, the journal of the American Heart Association, Vanderbilt University researchers published findings that the drug – a monoclonal antibody known as SYN0012 – shows promise in keeping heart valve leaflets… Read MoreFeb. 3, 2016